Docking to erlotinib off-targets leads to inhibitors of lung cancer cell proliferation with suitable in vitro pharmacokinetics

Liwei Li, Jing Li, May Khanna, Inha Jo, Jason P. Baird, Samy O. Meroueh

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

In an effort to develop a rational approach to identify anticancer agents with selective polypharmacology, we mined millions of docked protein?ligand complexes involving more than a thousand cancer targets from multiple signaling pathways to identify new structural templates for proven pharmacophores. Our method combines support vector machine-based scoring to enrich the initial library of 1592 molecules, with a fingerprint-based search for molecules that have the same binding profile as the EGFR kinase inhibitor erlotinib. Twelve new compounds were identified. In vitro activity assays revealed three inhibited EGFR with IC50 values ranging from 250 nM to 200 ?M. Additional in vitro studies with hERG, CYP450, DNA, and cell culture-based assays further compared their properties to erlotinib. One compound combined suitable pharmacokinetic properties while closely mimicking the binding profile of erlotinib. The compound also inhibited H1299 and H460 tumor cell proliferation. The other two compounds shared some of the binding profile of erlotinib, and one gave the most potent inhibition of tumor cell growth. Interestingly, among the compounds that had not shown inhibition of EGFR, four blocked H1299 and H460 proliferation, one potently with IC50 values near 1 ?M. This compound was from the menogaril family, which reached phase II clinical trials for the treatment of lymphomas. This suggests that our computational approach comparing binding profiles may have favored molecules with anticancer properties like erlotinib.

Original languageEnglish (US)
Pages (from-to)229-233
Number of pages5
JournalACS Medicinal Chemistry Letters
Volume1
Issue number5
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Pharmacokinetics
Cell proliferation
Lung Neoplasms
Cell Proliferation
Inhibitory Concentration 50
Molecules
Menogaril
Polypharmacology
Tumors
Assays
Neoplasms
Phase II Clinical Trials
Dermatoglyphics
Cell growth
Cell culture
Antineoplastic Agents
Libraries
Support vector machines
Lymphoma
Phosphotransferases

ASJC Scopus subject areas

  • Organic Chemistry
  • Drug Discovery
  • Biochemistry

Cite this

Docking to erlotinib off-targets leads to inhibitors of lung cancer cell proliferation with suitable in vitro pharmacokinetics. / Li, Liwei; Li, Jing; Khanna, May; Jo, Inha; Baird, Jason P.; Meroueh, Samy O.

In: ACS Medicinal Chemistry Letters, Vol. 1, No. 5, 2010, p. 229-233.

Research output: Contribution to journalArticle

@article{6b7ddadc0ca94ca39c18a3adabd1cd77,
title = "Docking to erlotinib off-targets leads to inhibitors of lung cancer cell proliferation with suitable in vitro pharmacokinetics",
abstract = "In an effort to develop a rational approach to identify anticancer agents with selective polypharmacology, we mined millions of docked protein?ligand complexes involving more than a thousand cancer targets from multiple signaling pathways to identify new structural templates for proven pharmacophores. Our method combines support vector machine-based scoring to enrich the initial library of 1592 molecules, with a fingerprint-based search for molecules that have the same binding profile as the EGFR kinase inhibitor erlotinib. Twelve new compounds were identified. In vitro activity assays revealed three inhibited EGFR with IC50 values ranging from 250 nM to 200 ?M. Additional in vitro studies with hERG, CYP450, DNA, and cell culture-based assays further compared their properties to erlotinib. One compound combined suitable pharmacokinetic properties while closely mimicking the binding profile of erlotinib. The compound also inhibited H1299 and H460 tumor cell proliferation. The other two compounds shared some of the binding profile of erlotinib, and one gave the most potent inhibition of tumor cell growth. Interestingly, among the compounds that had not shown inhibition of EGFR, four blocked H1299 and H460 proliferation, one potently with IC50 values near 1 ?M. This compound was from the menogaril family, which reached phase II clinical trials for the treatment of lymphomas. This suggests that our computational approach comparing binding profiles may have favored molecules with anticancer properties like erlotinib.",
author = "Liwei Li and Jing Li and May Khanna and Inha Jo and Baird, {Jason P.} and Meroueh, {Samy O.}",
year = "2010",
doi = "10.1021/ml100031a",
language = "English (US)",
volume = "1",
pages = "229--233",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "5",

}

TY - JOUR

T1 - Docking to erlotinib off-targets leads to inhibitors of lung cancer cell proliferation with suitable in vitro pharmacokinetics

AU - Li, Liwei

AU - Li, Jing

AU - Khanna, May

AU - Jo, Inha

AU - Baird, Jason P.

AU - Meroueh, Samy O.

PY - 2010

Y1 - 2010

N2 - In an effort to develop a rational approach to identify anticancer agents with selective polypharmacology, we mined millions of docked protein?ligand complexes involving more than a thousand cancer targets from multiple signaling pathways to identify new structural templates for proven pharmacophores. Our method combines support vector machine-based scoring to enrich the initial library of 1592 molecules, with a fingerprint-based search for molecules that have the same binding profile as the EGFR kinase inhibitor erlotinib. Twelve new compounds were identified. In vitro activity assays revealed three inhibited EGFR with IC50 values ranging from 250 nM to 200 ?M. Additional in vitro studies with hERG, CYP450, DNA, and cell culture-based assays further compared their properties to erlotinib. One compound combined suitable pharmacokinetic properties while closely mimicking the binding profile of erlotinib. The compound also inhibited H1299 and H460 tumor cell proliferation. The other two compounds shared some of the binding profile of erlotinib, and one gave the most potent inhibition of tumor cell growth. Interestingly, among the compounds that had not shown inhibition of EGFR, four blocked H1299 and H460 proliferation, one potently with IC50 values near 1 ?M. This compound was from the menogaril family, which reached phase II clinical trials for the treatment of lymphomas. This suggests that our computational approach comparing binding profiles may have favored molecules with anticancer properties like erlotinib.

AB - In an effort to develop a rational approach to identify anticancer agents with selective polypharmacology, we mined millions of docked protein?ligand complexes involving more than a thousand cancer targets from multiple signaling pathways to identify new structural templates for proven pharmacophores. Our method combines support vector machine-based scoring to enrich the initial library of 1592 molecules, with a fingerprint-based search for molecules that have the same binding profile as the EGFR kinase inhibitor erlotinib. Twelve new compounds were identified. In vitro activity assays revealed three inhibited EGFR with IC50 values ranging from 250 nM to 200 ?M. Additional in vitro studies with hERG, CYP450, DNA, and cell culture-based assays further compared their properties to erlotinib. One compound combined suitable pharmacokinetic properties while closely mimicking the binding profile of erlotinib. The compound also inhibited H1299 and H460 tumor cell proliferation. The other two compounds shared some of the binding profile of erlotinib, and one gave the most potent inhibition of tumor cell growth. Interestingly, among the compounds that had not shown inhibition of EGFR, four blocked H1299 and H460 proliferation, one potently with IC50 values near 1 ?M. This compound was from the menogaril family, which reached phase II clinical trials for the treatment of lymphomas. This suggests that our computational approach comparing binding profiles may have favored molecules with anticancer properties like erlotinib.

UR - http://www.scopus.com/inward/record.url?scp=77956166424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956166424&partnerID=8YFLogxK

U2 - 10.1021/ml100031a

DO - 10.1021/ml100031a

M3 - Article

AN - SCOPUS:77956166424

VL - 1

SP - 229

EP - 233

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

SN - 1948-5875

IS - 5

ER -